We also observed a higher proportion of terminally exhausted and dysfunctional CD8+ T cells (PD1+CD38+) after anti-PD1 treatment in idMMR neuroblastoma tumors (Figure 3O). This evidence concerns the gene CD38 and neuroblastoma.